Advice

in the absence of a submission from the holder of the marketing authorisation:

alectinib hydrochloride (Alecensa®) is not recommended for use within NHS Scotland.

Indication under review: As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase positive advanced non-small cell lung cancer previously treated with crizotinib.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Download detailed advice68KB (PDF)

Download

Medicine details

Medicine name:
alectinib hydrochloride (Alecensa)
SMC ID:
1257/17
Indication:
As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase positive advanced non-small cell lung cancer previously treated with crizotinib.
Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Not recommended
Date advice published:
08 May 2017